X-10 Pathology, Empowering diagnostics

Información del proyecto

X-10 Pathology

Identificador del acuerdo de subvención: 734969

DOI

10.3030/734969

Proyecto cerrado

Fecha de la firma de la CE 11 Julio 2016

Fecha de inicio 1 Agosto 2016

Fecha de finalización 31 Diciembre 2016

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

GRADEMI BIOTECH SRL
Italy

Periodic Reporting for period 1 - X-10 Pathology (X-10 Pathology, Empowering diagnostics)

Período documentado: 2016-08-01 hasta 2016-12-31

Resumen del contexto y de los objetivos generales del proyecto

X-10 Pathology is a novel point-of-care in vitro diagnostic (IVD) instrument that is unique in its ability to specifically diagnose a set of inflammatory conditions with a single, inexpensive blood test.
The late diagnosis of inflammatory pathologies, such as cancer and autoimmune diseases, puts undue burden on patients, caregivers, and healthcare systems. This year alone, more than 50 million people around the world will be diagnosed with an inflammatory disease. Patients, caregivers, and healthcare systems are increasingly demanding diagnostic tools that are cheaper, faster, and more accurate than existing technologies.
The mission of Grademi Biotech is to improve the quality of life of patients who are suffering from inflammatory diseases by reducing the need for long series of medical tests and specialist consultations before obtaining a reliable treatment.

Our vision is to extend this improvement in quality of life to all patients with inflammatory diseases worldwide, and to help reduce the global cost of healthcare.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

During the course of the Feasibility Study we have validated X-10 Pathology’s ability to diagnose two diseases in collaboration with the Hospital San Raffaele in Milan, Italy. The data collected during this stage show that, using X-10 Pathology on a large collection of blood samples, (A) patients with these two diseases can be distinguished from healthy patients and (B) that the two diseases may be readily distinguished from each other. Preliminary statistical analysis has provided an initial model of the reference curves for these two diseases, which will be further refined by recruiting more patients during the course of Phase 2.

Additionally, to ensure that all samples undergo identical treatment prior to analysis we have designed a sample shaker to be sold with the X-10 Pathology instrument. The shaker will hold 8 samples –the same as the X-10 Pathology apparatus – and will allow for adjustments to be made to the sample speed, shaking time, and sample angle.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The technical advances made during the project so far, along with our greater understanding of the IVD market at large, indicate to us that X-10 Pathology could have a large impact on healthcare both in the developed and developing world. The implications of our success would mean faster and cheaper access to important diagnostic decisions for a large number of underserved patients.

image-1.png